NTLA vs QCLS

Intellia Therapeutics, Inc. vs Q/C Technologies, Inc. — Valuation Comparison 2026

NTLA

In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$14.07
Last close
Models
9/13
Active
VS

QCLS

In Vitro & In Vivo Diagnostic Substances
Q/C Technologies, Inc.
Quality
4.0
out of 10
Value Trap
25
LOW
Price
$4.37
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType NTLA Fair ValueNTLA Upside QCLS Fair ValueQCLS Upside
Bayesian DCF Intrinsic $3.57 -74.7% $1.21 -72.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.55 -95.5% $0.36 -90.5%
Dynamic NAV Asset-Based $6.80 -51.7% $0.11 -97.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NTLA vs QCLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NTLA vs QCLS — Which Stock Is More Undervalued?

NTLA scores higher with a 6.5/10 quality rating vs QCLS's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intellia Therapeutics, Inc. (NTLA) and Q/C Technologies, Inc. (QCLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NTLA currently trades at $14.07 with a QOC of 6.5/10, while QCLS trades at $4.37 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).